|350.39||-1.16||-0.33%||Vol 112.17K||1Y Perf -17.83%|
|Oct 3rd, 2023 15:59 DELAYED|
|- -%||- -|
|Target Price||621.67||Analyst Rating||Strong Buy 1.25|
|Potential %||76.99||Finscreener Ranking||★★★★+ 56.00|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★+ 52.34|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★ 45.15|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||3.49||Earnings Rating||Strong Sell|
|Market Cap||10.19B||Earnings Date||26th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Oct 2023|
|Estimated EPS Next Report||2.87|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||115.16K|
|Avg. Monthly Volume||168.49K|
|Avg. Quarterly Volume||179.64K|
Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 351.55 per share at the end of the most recent trading day (a -1.92% change compared to the prior day closing price) with a volume of 123.37K shares and market capitalization of 10.19B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.
The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -17.83%, while year-to-date (YTD) performance is -16.4%. BIO stock has a five-year performance of 14.81%. Its 52-week range is between 344.63 and 509.6225, which gives BIO stock a 52-week price range ratio of 3.49%
Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.48, a price-to-sale (PS) ratio of 5.09, a price to cashflow ratio of 47.80, a PEG ratio of 0.40, a ROA of -41.67%, a ROC of -47.65% and a ROE of -56.29%. The company’s profit margin is -69.91%, its EBITDA margin is -273.90%, and its revenue ttm is $2.07 Billion , which makes it $83.72 revenue per share.
Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.87 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 26th Oct 2023.
The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1.25), with a target price of $621.67, which is +76.99% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bio-Rad Laboratories Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 9.51, ATR14 : 8.85, CCI20 : -93.78, Chaikin Money Flow : -0.19, MACD : -8.30, Money Flow Index : 61.01, ROC : -5.82, RSI : 36.62, STOCH (14,3) : 12.18, STOCH RSI : 0.47, UO : 40.93, Williams %R : -87.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Sold 0 shares of value $0 ), Ajit Ramalingam (Sold 396 shares of value $166 315 ), Crowley Michael (Sold 500 shares of value $189 695 ), Dara Wright (Option Excercise at a value of $0), Daskal Ilan (Sold 0 shares of value $0 ), Ernst Timothy (Option Excercise at a value of $167 819), Ernst Timothy (Sold 1 746 shares of value $849 300 ), Ilan Daskal (Option Excercise at a value of $0), Last Andrew (Sold 0 shares of value $0 ), Timothy S. Ernst (Option Excercise at a value of $167 819), Timothy S. Ernst (Sold 1 746 shares of value $849 300 )
Wed, 30 Aug 2023 01:45 GMT Bio-Rad Laboratories (BIO) Receives a Buy from RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.